Burning Rock Biotech (BNR) Current Deferred Revenue (2019 - 2025)

Burning Rock Biotech's Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $15.2 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue fell 7.38% year-over-year to $15.2 million; the TTM figure through Dec 2025 stood at $15.2 million (down 7.38% YoY), while the FY2025 annual figure was $15.4 million, down 4.54% from the prior year.
• Current Deferred Revenue was $15.2 million for Q4 2025 at Burning Rock Biotech, up from $15.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $25.1 million in Q1 2022 to a low of $3.0 million in Q2 2022.
• Historically, Current Deferred Revenue has averaged $17.6 million across 5 years, with a median of $17.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue plunged 80.8% in 2022, then soared 572.9% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $22.3 million in 2021, then decreased by 7.11% to $20.8 million in 2022, then slipped by 12.66% to $18.1 million in 2023, then dropped by 9.47% to $16.4 million in 2024, then fell by 7.38% to $15.2 million in 2025.
• The last three Current Deferred Revenue figures came in at $15.2 million (Q4 2025), $15.0 million (Q3 2025), and $14.4 million (Q2 2025), per Business Quant data.